

# Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study

*Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHIFT study*

Nick van Boven, K. Martijn Akkerhuis, Sharda S. Anroedh, Dimitris Rizopoulos, Yigal Pinto, Linda C. Battes, Hans L. Hillege, Kadir C. Caliskan, Tjeerd Germans, Olivier C. Manintveld, Jan-Hein Cornel, Alina A. Constantinescu, Eric Boersma, Victor A. Umans, Isabella Kardys.

International Journal of Cardiology 235 (2017) 124–132

## ABSTRACT

**Background:** Several studies have suggested circulating microRNAs (miRs) are associated with heart failure, but these studies were small, and limited to single miR measurements. We examined 7 miRs which were previously linked to heart failure, and tested whether their temporal expression level predicts prognosis in a prospective cohort of chronic heart failure (CHF) patients.

**Methods:** In 2011-2013, 263 CHF patients were included. At inclusion and subsequently every 3 months, we measured 7 miRs. The primary endpoint (PE) comprised heart failure hospitalization, cardiovascular mortality, cardiac transplantation and LVAD implantation. Associations between temporal miR patterns and the PE were investigated by joint modelling, which combines mixed models with Cox regression.

**Results:** Mean age was 67±13 years, 72% were men and 27% NYHA class III–IV. We obtained 873 blood samples (median 3 [IQR 2-5] per patient). The PE was reached in 41 patients (16%) during a median follow-up of 0.9 [0.6-1.4] years. The temporal pattern of miR-22-3p was independently associated with the PE (HR [95% CI] per doubling of level: 0.64 [0.47 - 0.77]). The instantaneous change in level (slope of the temporal miR pattern) of miR-22-3p was also independently associated with the PE (HR [95% CI] per doubling of slope: 0.33 [0.20–0.51]). These associations remained statistically significant after adjustment for temporal patterns of NT-proBNP, Troponin T and CRP.

**Conclusions:** The temporal pattern of circulating miR-22-3p contains important prognostic and independent information in CHF patients. This concept warrants further investigation in larger series with extended follow-up.

## INTRODUCTION

Contemporary treatment of chronic heart failure ((C)HF) generally aims to stabilize or at least decelerate disease progression. Adjustment of pharmacotherapy is largely based on clinical judgement and thus mostly relies on the worsening of symptoms or signs.<sup>1,2</sup> However, in the context of the complexity of HF therapy, considerable clinical skills, as well as cooperation of the patients, are required to recognize opportunities to titrate therapies and to implement such changes intervene early and timely.<sup>3</sup> Consequently, higher-risk patients may be undertreated.<sup>3</sup> Blood biomarkers have the potential to monitor subtle changes in the heart that reflect and possibly predict adverse changes before they become clinically apparent or reported.<sup>4</sup> The value of biomarkers, such as B-type natriuretic peptides (BNP), cardiac troponins and C- reactive protein (CRP), for risk stratification of CHF patients has already been demonstrated.<sup>5-8</sup> Moreover, natriuretic peptide-guided HF therapy has recently been given a class IIa recommendation in US HF guidelines to achieve guideline-directed medical therapy.<sup>2,9</sup>

Nevertheless, the predictive capability of the aforementioned biomarkers for worsening of CHF still leaves room for improvement. MicroRNAs (miRs) are upcoming novel biomarkers that seem promising for early diagnosis and treatment of HF. MiRs are non-coding, ~22 nucleotide long RNA sequences, which target messenger RNAs for cleavage or translational repression and thereby influence a great variety of biological processes.<sup>10</sup> The stability of miRs in plasma, and consequently their reliable assessment in easily accessible samples, potentially makes them attractive biomarkers for a wide range of diseases.<sup>11</sup> Studies revealing that deletion of Dicer, a gene encoding an RNase III endonuclease essential for miR processing, leads to cardiac remodeling and dilation, were the first to show involvement of miRs in HF<sup>12,13</sup> and to suggest that miRs might be used as biomarkers for cardiovascular diseases.<sup>14</sup> Several other studies have subsequently shown associations between miRs and myocardial infarction<sup>15-18</sup> and HF.<sup>19-24</sup> However, most studies pertaining to HF were performed in case-control settings and had a limited sample size. Furthermore, these studies usually assessed miRs only once. Repeated, longitudinal miR assessment in CHF patients may, however, provide insight into individual, tem-

poral patterns and the patient's ensuing risk of disease progression. The temporal patterns of miRs in patients with known CHF have not yet been investigated.

In the current prospective, observational study, we have performed frequent (up to 8), repeated measurements of multiple miRs that were previously linked to HF (miR-1254, miR-22-3p, miR-423-5p, miR-486-5p and miR-320a) or have been shown to be cardiac-enriched (miR-345-5p, miR-378a-3p) in a cohort of 263 outpatients with CHF, and have subsequently investigated the associations of the obtained temporal patterns with adverse clinical outcome during follow-up.

## METHODS

### Patients

The Serial biomarker measurements and new echocardiographic techniques in chronic heart failure patients result in tailored prediction of prognosis (Bio-SHiFT) study was designed to investigate the relationship between temporal patterns of biomarkers involved in CHF and prognosis. Bio-SHiFT is an ongoing prospective, observational study of stable outpatients with CHF, conducted in Erasmus MC, Rotterdam, The Netherlands and Medical Centre Alkmaar, The Netherlands. Patients were recruited during their regular outpatient visits and were in clinically stable condition. Patients were eligible for inclusion if aged 18 years or older, capable of understanding and signing informed consent, and if CHF (including HF with preserved ejection fraction (HFPEF)) was diagnosed  $\geq 3$  months ago according to the guidelines of the European Society of Cardiology (ESC).<sup>25-27</sup> Detailed inclusion and exclusion criteria are shown in figure 1. The study was approved by the medical ethics committees of the participating hospitals and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients. The study is registered in ClinicalTrials.gov, number NCT01851538. In the current paper, we have performed an analysis on the 263 patients who were enrolled during the first inclusion period between October 2011 and June 2013. Follow-up for this analysis lasted from October 2011 until November 2013.

### Baseline assessment

At baseline patients were evaluated by trained research physicians, who collected information on HF related symptoms including NYHA class<sup>25,26</sup> and performed a physical examination, including blood pressure, heart rate and body mass

index. Information on aetiology of heart failure, presence of systolic dysfunction, cardiovascular risk factors, medical history and medical treatment was retrieved primarily from hospital records and was completed by anamnesis in case of ambiguities. History of myocardial infarction, percutaneous coronary intervention (PCI), coronary artery bypass grafting, valvular heart disease, atrial fibrillation or other arrhythmias, device implantation, cerebrovascular accident, diabetes mellitus, hypercholesterolemia, hypertension, and sleep apnea were defined as a clinical diagnosis of these conditions, as reported by the treating physician in the medical chart. History of chronic renal failure was defined as glomerular filtration rate less than 60 mL/min/1.73 m<sup>2</sup>. Alcohol consumption was defined as drinking  $\geq 1$  alcoholic consumption per day. Electrocardiography and echocardiography were performed. Data were entered into electronic case report forms. Non-fasting blood and urine samples were collected.




Figure 1 - Inclusion and exclusion criteria

### Follow-up visits

All patients continued routine outpatient visits during the study. Study follow-up visits were scheduled every 3 months (a window of  $\pm 1$  month was allowed), for a maximum of 30 months. For patients' convenience, study visits and routine outpatient visits were combined when possible. At each tri-monthly study visit, a short medical evaluation was performed and blood and urine samples were collected. Adverse cardiovascular events and changes in medication were recorded in electronic case report forms.

### Blood sampling and miR measurement

Blood samples were collected at baseline and at each follow-up visit, and were processed and stored locally at a temperature of  $-80^{\circ}\text{C}$  within 2 hours after blood collection. When applicable, samples were transported to the central laboratory (Erasmus MC, Rotterdam, The Netherlands) under controlled conditions (at a temperature of  $-80^{\circ}\text{C}$ ), until batch analysis took place. Accordingly, results of the biomarker assays were not available to treating physicians at the time of the outpatient visits. Thus, the biomarker measurements did not lead to treatment adjustments, and all patients received usual care based on European guidelines.<sup>25,26</sup>

For the purpose of the current investigation, stored plasma samples were transported under controlled conditions to ACS Biomarker, Amsterdam, The Netherlands, and seven miRs were measured in one batch: miR-1254, miR-22-3p, miR-345-5p, miR-378a-3p, miR-423-5p, miR-486-5p and miR320a. MiR-1254, miR-22-3p, miR-423-5p, miR-486-5p and miR-320a were selected because they were associated with HF in previous studies.<sup>11,21,24</sup> MiR-378a-3p and miR-345-5p were selected because of their presence in cardiomyocytes.<sup>28</sup> Plasma was thawed on ice and RNA isolation was performed using the TRIZOL LS reagent (Life Technology) according to the manufacturer's protocol, with a starting volume of 200ul plasma. Subsequently, 8ul of the eluate from the RNA isolation was used for the reverse transcription reaction. The transcription followed the manufacturer's protocol of the miScript Reverse Transcription Kit (Qiagen). For real-time PCR, 2ul of 10x diluted cDNA was used in a total volume of 10ul. The real-time PCR reaction was performed on a LightCycler 480 using the following program: 5 min of pre-incubation at  $95^{\circ}\text{C}$ ; 10 sec of denaturation at  $95^{\circ}\text{C}$ , 20 sec of annealing at  $58^{\circ}\text{C}$  and 30 sec of elongation at  $72^{\circ}\text{C}$ , in a total of 45 cycles. Data were analyzed with LinRegPCR quantitative PCR data analysis software. MiR values were normalized using exogenous *C. elegans* miR-39 as a spike-in control, which was applied prior to the RNA isolation step. The

forward primers used were: miR-423-5p: TGAGGGGCAGAGAGCGAGACTTT; miR-22-3p: AAGCTGCCAGTTGAAGAACTGT; miR-378a-3p: ACTGGACTTGGAGTCAGAAGG; miR-1254: CTGGAAGCTGGAGCCTGC; miR-345-5p: GCTGACTCCTAGTCC; miR-486-5p: TCCTGTACTGAGCTG; miR-320a: AAAAGCTGGGTTGAGAGGGCGA.

Batch analysis of N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitive cardiac troponin T (HsTNT) and C-reactive protein was performed in the Clinical Chemistry Laboratory of the Erasmus MC, Plasma NT-proBNP and cardiac Troponin T were analyzed using electrochemiluminescence immunoassays (Roche Diagnostics, Elecsys 2010, Indianapolis, Indiana, USA), measuring concentrations ranging from 5 to 35000 ng/L and 3 to 10000 ng/L, respectively. CRP was measured using an immunoturbidimetric assay (Roche Hitachi 912 chemistry analyzer, Basel, Switzerland), which measures concentrations ranging from 0.3 to 350 mg/L.

### **Clinical study endpoints**

During follow-up, endpoints were recorded in the electronic case report forms by trained research physicians, and associated hospital records and discharge letters were collected. A clinical event committee blinded to the biomarker results subsequently reviewed all collected information and adjudicated primary and secondary endpoints.

The primary endpoint comprised the composite of cardiac death, cardiac transplantation, left ventricular assist device implantation, and hospitalization for the management of acute or worsened HF. Secondary endpoints included individual components of the primary endpoint, as well as myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, cerebrovascular accident, and all-cause mortality.

Cardiac death was defined as death from myocardial infarction or other ischemic heart disease (ICD-10: I20-I25), death from other heart disease including HF (I30-I45 and I47-I52), sudden cardiac death (I46), sudden death undefined (R96) or unwitnessed or ill-described death (R98, R99). Hospitalization for acute or worsened HF was defined as exacerbation of symptoms typical of HF, in combination with 2 of the following: BNP or NT-proBNP >3x ULN, signs of worsening HF, such as pulmonary rales, raised jugular venous pressure or peripheral edema, increased dose or intravenous administration of diuretics, or administration of positive inotropic agents.

## Statistical analysis

Distributions of continuous variables, including biomarker and miR concentrations, were tested for normality using the Kolmogorov-Smirnov test. Variables with normal distributions are presented as mean $\pm$ SD. Variables with non-normal distributions are presented as median and interquartile range (IQR). Categorical data are displayed as count and percentage.

In case of skewed distributions, continuous variables were logarithmically transformed for further analyses. Associations between temporal patterns of each separate miR and the primary endpoint were assessed using a joint modelling approach, which combines a linear mixed-effects model for the serial miR measurements with a Cox proportional hazards model for the occurrence of the primary endpoint. Results are presented as hazard ratios (HRs) per doubling of the miR concentration at any point in time, along with the corresponding 95% CIs. All analyses were adjusted for age and gender. Subsequently, additional multivariable adjustment for potential confounding variables was performed. For this purpose, associations between patient characteristics and baseline miR levels, as well as associations between patient characteristics and the primary endpoint, were identified using univariable linear- or Cox regression analyses, when appropriate. All characteristics associated with the miRs or the primary endpoint were subsequently used as covariates in the mixed-effects and Cox models used to construct the joint models. Adjustment for repeatedly assessed NYHA class was performed by entering NYHA class as a time-dependent variable into the joint model.

The above-described analysis assesses the predictive value of the temporal pattern of the actual miR measurements. However, additional features of the miR's trajectory may better predict the primary endpoint.<sup>29,30</sup> Therefore, we investigated whether the instantaneous rate of change in miR (slope of the miR trajectory) is associated with the risk of the primary endpoint. Furthermore, to assess the predictive value of long-term elevation of miR levels, we investigated the associations between the area under the miRs' trajectory and the primary endpoint. This area can be considered as a weighted average of the total longitudinal profile of each patient. The results are presented as HRs per doubling of the area at any point in time, with 95% CIs.

Subsequently, we assessed whether the predictive value of the temporal miR patterns was independent of temporal patterns of NT-proBNP, HsTNT and CRP. For this purpose, all individual temporal miR patterns (of miRs significantly associated with the primary endpoint), as well as NT-proBNP, HsTNT and CRP patterns, derived from



the adjusted joint models were saved and subsequently entered simultaneously as time-varying covariates into an extended Cox analysis. The same approach was used to investigate the independent predictive value of the slope and the area under the curve of the temporal miR patterns associated with the primary endpoint.


To investigate the associations between repeated miR measurements and repeated NT-proBNP, HsTNT and CRP measurements, we used generalised estimating equations. Herewith, we examined whether the miR level at a certain time-point is associated with the level of the other biomarkers at that same time-point.

All analyses were performed with R Statistical Software using package JM.29,30 All tests were two-tailed and p-values <0.05 were considered statistically significant.

## RESULTS

### Baseline characteristics

From October 2011 to June 2013, 263 patients were included. Mean age was 67 years (SD  $\pm$ 13), 72% were men, and 73% were in New York Heart Association (NYHA) class I or II (Table 1). Median baseline NT-proBNP was 139.6 pmol/L (IQR 51.9 – 272.9), HsTNT 18.0 ng/L (IQR 9.6 – 33.2) and CRP 2.2 mg/L (IQR 0.9 – 4.8). Median duration of HF at inclusion was 4.6 years (IQR 1.7 – 9.9). Associations between patient characteristics and baseline miR measurements are presented in the supplementary table. Of note is the presence of a significant association between ischemic cardiomyopathy (ICM) and several miRs. This is further illustrated in figure 2. No significant associations were present with other baseline characteristics.



**Figure 2** - Associations between baseline MicroRNA levels and presence of ischemic cardiomyopathy

Odds ratios for doubling of microRNA (miR) expression level

**Table 1 – Baseline characteristics**

	Total (n=263)
<b>Demographics</b>	
Age	67 (±13)
Male gender	189 (72)
Caucasian ethnicity	244 (94)
<b>Clinical characteristics</b>	
Body mass index kg/m <sup>2</sup>	28 (±5)
Heart rate, bpm	67 (±12)
Systolic blood pressure, mmHg	122 (±20)
Diastolic blood pressure, mmHg	73 (±11)
<b>Biomarker level</b>	
NT-proBNP (pmol/L)	139.6 (51.9 – 272.9)
HsTNT (ng/L)	18.0 (9.6 – 33.2)
CRP (mg/L)	2.2 (0.9 – 4.8)
<b>Features of heart failure</b>	
Duration of heart failure, years	4.6 (1.7 – 9.9)
NYHA class I	75 (29)
NYHA class II	115 (44)
NYHA class III or IV	69 (27)
Left ventricular function	
Systolic dysfunction	250 (95)
HFPEF	13 (5)
LVEF*	32 (±10)
<b>Etiology of heart failure</b>	
Ischemic heart disease	117 (44)
Hypertension	34 (13)
Secondary to valvular heart disease	12 (5)
Cardiomyopathy	68 (26)
Dilated	49 (19)
Hypertrophic	12 (5)
Non compaction	4 (1)
Unclassified	3 (1)
Unknown	19 (7)
Other	13 (5)
<b>Medical history</b>	
Myocardial infarction	94 (36)
PCI	82 (31)
CABG	43 (16)
Valvular heart disease	136 (53)
Atrial fibrillation	105 (40)
Other arrhythmia	82 (32)
ICD	151 (59)
CRT	78 (30)
Pacemaker	38 (15)
CVA	41 (16)

**Table 1** – Baseline characteristics (*continued*)

	Total (n=263)
Chronic renal failure	136 (53)
Diabetes Mellitus	81 (31)
Known hypercholesterolemia	93 (35)
Hypertension	120 (46)
Sleep apnea	26 (10)
<b>Intoxications</b>	
Alcohol consumption (>1 unit/day)	108 (42)
Smoking	185 (71)
Ever	186 (72)
Current	26 (10)
<b>Medication use</b>	
ACE-i	173 (67)
ARB	75 (29)
Aldosteron antagonist	178 (68)
Diuretic	237 (90)
Beta-blocker	232(88)
Aspirin	45 (17)
Vitamin K antagonist	200 (77)
Nitrates	44 (17)
Digoxin	59 (23)
Antiarrhythmics	39 (15)

Normally distributed continuous variables are presented as mean ( $\pm$  standard deviation). Non-normally distributed continuous variables are expressed as median (25<sup>th</sup> – 75<sup>th</sup> percentile). Categorical variables are expressed as count (percentage). Valid percentages may vary for some counts, because of missing values. ACE-I = ace inhibitor; ARB = angiotensin II receptor blocker; CABG = coronary artery bypass grafting; COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; CRT = cardiac resynchronization therapy; CVA = cerebrovascular accident; HFPEF = heart failure with preserved ejection fraction; HsTNT = high sensitive cardiac troponin T; ICD = implantable cardioverter / defibrillator; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-B-type natriuretic peptide NYHA = New York heart association; PCI = percutaneous coronary intervention.

\* Baseline echocardiograms were available in 72% of all patients because of logistic reasons.

### Clinical endpoints

The primary, composite endpoint was reached by 41 patients (16%), during a median follow-up of 0.9 [0.6-1.4] years: 5 patients died from a cardiovascular cause, 35 patients were re-hospitalized for worsened HF and 1 patient underwent heart transplantation. Of the 35 patients reaching the primary endpoint because of re-hospitalization for HF, 16 patients died eventually during further follow-up, of whom 12 died from a cardiovascular cause. Overall all-cause mortality was thus 21 (8.0%).

Of all baseline variables, NYHA class (HR 1.98; CI 1.24 – 3.16 for III/IV vs I/II), baseline NT-proBNP (HR per two-fold difference of baseline NT-proBNP 1.42; CI 1.09 – 1.86), and baseline CRP (HR per two-fold difference of baseline CRP 1.29; CI 1.05 – 1.60) were independently associated with the primary endpoint. As shown in table 2, none of the baseline miR values were associated with the primary endpoint, or the secondary endpoint comprising HF hospitalizations only.

**Table 2** – Associations between baseline miRs and the primary endpoint and secondary endpoint

	Primary endpoint		Secondary endpoint	
	HR* (95% CI)	P	HR (95% CI)	P
<b>miR-1254</b>	1.01 (0.92–1.09)	0.91	1.00 (0.91–1.09)	0.99
<b>miR-22-3p</b>	1.02 (0.93–1.12)	0.61	1.00 (0.90–1.09)	0.85
<b>miR-345-5p</b>	0.99 (0.89–1.09)	0.81	0.95 (0.86–1.06)	0.38
<b>miR-378a-3p</b>	1.00 (0.91–1.11)	0.93	0.99 (0.89–1.09)	0.77
<b>miR-423-5p</b>	1.01 (0.91–1.11)	0.92	0.97 (0.87–1.07)	0.53
<b>miR-486-5p</b>	1.04 (0.94–1.15)	0.47	1.00 (0.89–1.11)	0.93
<b>miR-320a</b>	1.04 (0.95–1.13)	0.44	1.02 (0.93–1.12)	0.71


miR = microRNA.

Primary endpoint: cardiac death, cardiac transplantation, left ventricular assist device implantation, and hospitalization for the management of acute or worsened heart failure; secondary endpoint: hospitalization for the management of acute or worsened heart failure.

\* Hazard ratios (HRs) and corresponding confidence intervals (CIs) were calculated using Cox regression analyses and are given per doubling of level of miR.

### Temporal miR patterns and the primary endpoint

During follow-up, we collected 923 blood samples, of which 885 were drawn before the occurrence of the primary endpoint (median of 3 (IQR 2-5) samples per patient). MiRs were successfully determined in 873 of these samples. The temporal pattern of miR-22-3p was inversely associated with the primary endpoint (age and gender adjusted HR per doubling of miR-22-3p level, 0.64; CI 0.47 - 0.77;  $p < 0.001$ ), i.e. higher miR-22-3p was associated with lower risk of events (table 3). As described above, baseline measurements of several miRs were associated with ICM. On the other hand, NYHA class was independently associated with the primary endpoint. Therefore, the baseline variables ICM and NYHA class were added to the models. After adjustment for age, gender, NYHA class and ICM, the association between the temporal pattern of miR-22-3p and the primary endpoint remained present (HR per doubling of miR-22-3p level 0.71; CI 0.44 - 0.94;  $p = 0.005$ ). When serial NYHA class assessments were added to the model instead of baseline NYHA assessments only,



**Figure 3** - Temporal evolution of microRNA levels

Temporal evolution was estimated by using mixed models. Y-axis: arbitrary units [a.u.] representing relative miRNA expression levels. X-axis: time in years as the endpoint approaches (time=0 denotes the moment that the endpoint occurs for the patients reaching the endpoint, and the moment of right-censoring for the patients not reaching the endpoint). Red solid line: miR expression level in patients reaching the endpoint. Red dotted lines: 95% confidence interval. Black solid line: miR expression level in patients not reaching the endpoint. Black dotted line: 95% confidence interval.

**Table 3** - Associations between temporal miR patterns and the primary endpoint

	miR-1254		miR-22-3p		miR-345-5p		miR-378a-3p	
	HR* (95% CI)	p	HR* (95% CI)	p	HR* (95% CI)	p	HR* (95% CI)	p
<b>Temporal pattern of miR value</b>								
Adjusted for age and gender	1.02 (0.71–1.26)	0.782	0.64 (0.47–0.77)	<0.001	1.01 (0.97–1.04)	0.624	0.84 (0.69–1.03)	0.085
Multivariable adjusted <sup>y</sup>	0.97 (0.78–1.22)	0.757	0.71 (0.44–0.94)	0.005	1.00 (0.97–1.03)	0.921	0.88 (0.71–1.06)	0.148
<b>Slope of temporal pattern</b>								
Adjusted for age and gender	1.29 (0.75–2.49)	0.456	0.20 (0.09–0.50)	<0.001	NA	NA	NA	NA
Multivariable adjusted <sup>y</sup>	1.30 (0.79–2.35)	0.288	0.33 (0.20–0.51)	<0.001	NA	NA	NA	NA
<b>Area under the curve of temporal pattern</b>								
Adjusted for age and gender	1.09 (0.97–1.27)	0.206	1.00 (0.80–1.14)	0.898	NA	NA	NA	NA
Multivariable adjusted <sup>y</sup>	1.26 (0.95–1.53)	0.100	0.99 (0.88–0.17)	0.846	NA	NA	NA	NA

**Table 3** - Associations between temporal miR patterns and the primary endpoint (continued)

	miR-423-5p		miR-486-5p		miR-320a	
	HR* (95% CI)	p	HR* (95% CI)	p	HR* (95% CI)	p
<b>Temporal pattern of miR value</b>						
Adjusted for age and gender	1.01 (0.97–1.05)	0.800	1.00 (1.00–1.01)	0.069	0.92 (0.74–1.19)	0.516
Multivariable adjusted <sup>y</sup>	1.00 (0.95–1.08)	0.845	1.00 (0.99–1.01)	0.380	1.01 (0.78–1.22)	0.896
<b>Slope of temporal pattern</b>						
Adjusted for age and gender	NA	NA	NA	NA	0.51 (0.29–0.90)	0.012
Multivariable adjusted <sup>y</sup>	NA	NA	NA	NA	0.59 (0.33–1.12)	0.102
<b>Area under the curve of temporal pattern</b>						
Adjusted for age and gender	NA	NA	NA	NA	1.16 (0.94–1.42)	0.257
Multivariable adjusted <sup>y</sup>	NA	NA	NA	NA	1.19 (0.88–1.44)	0.330

miR = microRNA.

\* Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) are given per doubling of value, slope or area under the curve at any point in time.

<sup>y</sup> Adjusted for age, gender, New York Heart Association class and ischemic cardiomyopathy.

the association between miR miR-22-3p and the primary endpoint also remained present (HR per doubling of miR-22-3p level, 0.52; CI 0.44 - 0.61;  $p < 0.001$ ). The temporal patterns of the other 6 miRs were not significantly associated with the primary endpoint.

Baseline echocardiograms were available in 72% of all patients due to logistic reasons. After correction for left ventricular ejection fraction in this subgroup, miR-22-3p remained significantly associated with the primary endpoint (HR per doubling of miR-22-3p level, 0.91; CI 0.85 - 0.95;  $p < 0.001$ ).

Figure 3 shows that in the patients who reached the endpoint, miR-22-3p values declined as this endpoint approached, while in the patients who did not reach the endpoint, miR-22-3p values remained stable.

### **Slope and area under the curve of the temporal miR patterns and the primary endpoint**

The hazard ratios for the doubling of the slopes and areas under the curve of the temporal miR patterns are displayed in table 3. For 4 of the miRs (miR-345-5p, miR-378a-3p, miR-423-5p, and miR-486-5p), slopes remained virtually constant over time, and hazard ratios were not calculable. The slope of the temporal pattern of miR-22-3p was inversely associated with the primary endpoint after multivariable adjustment (HR per doubling of miR-22-3p slope at any given time point, 0.33; CI 0.20–0.51;  $p < 0.001$ ), while the slopes of the patterns of miR-1254 and miR-320a were not. None of the areas under the curves of the temporal miR patterns were associated with the primary endpoint.

### **Temporal patterns of miRs, NT-proBNP, Hs-TNT and CRP combined in a multiple-marker model**

After constructing the multivariable models that corrected for age, sex, ICM and NYHA class, we proceeded to additionally adjust the association between the temporal miR-22-3p pattern and the primary endpoint for temporal patterns of the other biomarkers which were measured in this study (NT-proBNP, HsTNT and CRP). We did this by entering the multivariably adjusted temporal pattern of miR-22-3p, as well as the multivariably adjusted temporal patterns of NT-proBNP, HsTNT and CRP simultaneously into one model. We found an independent association of miR-22-3p (HR per doubling of miR-22-3p level at any given time point, 0.61; CI 0.51–0.73;  $p < 0.001$ ) with the primary endpoint. Temporal patterns of NT-proBNP and CRP level were also independently associated with the primary endpoint in the

multiple-marker model (HRs: 1.34 (1.04–1.71) and 2.14 (1.59–2.88), respectively), while the temporal pattern of HsTNT was not (HR: 1.30 (0.91–1.84)). The slope of the temporal pattern of miR-22-3p also remained significantly associated with the primary endpoint after adjustment for the slopes of the temporal patterns of NT-proBNP, Troponin T and CRP (HR per doubling of miR-22-3p slope at any given time point, 0.55 (0.46–0.65);  $p < 0.001$ ).

### Repeated miR measurements and other biomarkers

Associations between repeatedly measured miR and repeatedly measured NT-proBNP, HsTNT and CRP, calculated using generalised estimating equations, are displayed in table 4. Of note are the significant inverse associations between miR-345-5p and CRP ( $\beta$ -coefficient [95%CI]: -0.04 [-0.07 – -0.01] 10log(mg/L) per 10log increase in miR-345-5p level;  $p=0.012$ ) and miR-22-3p and HsTNT ( $\beta$ -coefficient [95%CI]: -0.01 [-0.02 – -0.00] 10log(mg/L) per 10log increase in miR-22-3p level;  $p=0.014$ ; as well as the borderline significant inverse association between miR-22-3p and CRP ( $\beta$ -coefficient [95%CI]: -0.02 [-0.04 – 0.00] 10log(mg/L) per 10log increase in miR-22-3p level;  $p=0.051$ ). No further associations between repeatedly measured miR and repeatedly measured NT-proBNP, HsTNT and CRP were found.

**Table 4** – Associations between repeatedly measured miRs and B-type natriuretic peptide, high sensitive cardiac troponin T and C- reactive protein

	NT-proBNP		HsTNT		CRP	
	Beta coefficient (95% CI)	P	Beta coefficient (95% CI)	P	Beta coefficient (95% CI)	P
<b>miR-1254</b>	0.07 (-0.05 – 0.02)	0.27	0.00 (-0.01 – 0.01)	0.59	0.00 (-0.02 – 0.02)	0.92
<b>miR-22-3p</b>	-0.01 (-0.022 – -0.00)	0.14	-0.01 (-0.02 – -0.00)	0.014	-0.03 (-0.06 – 0.00)	0.051
<b>miR-345-5p</b>	-0.04 (-0.02 – 0.01)	0.57	-0.01 (-0.02 – 0.01)	0.35	-0.04 (-0.07 – -0.01)	0.012
<b>miR-378a-3p</b>	-0.01 (-0.02 – 0.00)	0.12	0.00 (-0.01 – 0.01)	0.91	-0.02 (-0.04 – 0.01)	0.27
<b>miR-423-5p</b>	0.00 (-0.02 – 0.01)	0.81	-0.01 (-0.02 – 0.00)	0.17	-0.01 (-0.04 – 0.03)	0.63
<b>miR-486-5p</b>	-0.01 (-0.02 – 0.01)	0.43	-0.01 (-0.02 – 0.01)	0.37	-0.03 (-0.06 – 0.00)	0.070
<b>miR-320a</b>	0.00 (-0.01 – 0.02)	0.69	0.00 (-0.01 – 0.01)	0.74	0.01 (-0.02 – 0.03)	0.71

Beta coefficients and corresponding 95% confidence intervals (CIs) were calculated using generalised estimating equations with 10log transformed microRNAs (miRs) as independent variables and 10log transformed N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitive cardiac troponin T (HsTNT) and C- reactive protein (CRP) as dependent variables.



## DISCUSSION

In this prospective, observational cohort of CHF patients, temporal miR-22-3p patterns were inversely and independently associated with adverse outcome. The association was independent of temporal NT-proBNP, HsTNT and CRP patterns. The instant rate of change in miR-22-3p level (in terms of the slope of the temporal pattern) was also inversely associated with adverse outcome. Moreover, we found inverse associations of temporal patterns of miR-22-3p with temporal patterns of HsTNT and CRP. An additional finding of this study was the significant, inverse association between ICM and miR-1254, miR486-5p and miR-320a.

Our study has several strengths. Although the number of incident endpoints was limited, this is the largest study to date that has examined miRs in a prospective cohort of patients with chronic HF. NT-proBNP, HsTNT and CRP were measured concomitantly, and, in addition, frequent repeated measurements were performed during follow-up, both of the miRs and of the established blood biomarkers. Statistical models containing all these, repeatedly measured, biomarkers were constructed and modern statistical methods were applied ('joint modelling'), which take into account the continuous, dynamic changes in biomarker patterns and thus result in less bias than simpler analyses such as delta's between two measurements. Here-with, the study expands existing evidence with regard to miRs and cardiovascular disease in several respects.

MiR-22-3p has previously received attention in the cancer field; it has been implicated in the regulation of various cellular processes, including cell growth, apoptosis, motility, and the cell cycle.<sup>31</sup> With regard to cardiovascular disease, fundamental experiments have demonstrated that expression of miR-22-3p is enriched in striated muscle tissues (i.e. cardiac and skeletal muscles); and miR-22-3p is thought to be required for normal cardiac remodeling in response to stresses.<sup>32</sup> A recent study in miR-22 deficient mice demonstrated that miR-22 depleted hearts quickly progress to adverse cardiac remodeling and develop cardiac dilation, with increased cardiomyocyte loss and deposition of fibrotic tissue, and signs of heart failure.<sup>33</sup> Another study also found that mice without miR-22 develop dilatation of myocardium more quickly.<sup>34</sup> Interestingly, several animal models have shown that miR-22 may potentially serve as a therapeutic target in cardiac hypertrophy.<sup>33</sup> Recently, Gupta et al found that pharmacological inhibition of miR-22 post-infarction activated cardiac autophagy, led to improved cardiac function, and inhibited cardiac remodeling in older mice.<sup>35</sup> They also found that circulating miR-22 provides prognostic information in HF patients. Specifically, they demonstrated

an association between higher baseline levels of circulating miR-22 and mortality in 154 HF patients. Repeated measurements were not performed. In the present study, although we saw a temporal decline of miR-22-3p levels in patients with adverse clinical outcome, we could not demonstrate a significant association between higher baseline miR-22-3p and clinical outcome. The shorter follow-up duration of our study (median of approx. 1 year, versus 3 years follow-up in the study of Gupta et al) may have contributed to this. Furthermore, in an earlier study, Goren et al, demonstrated that elevated serum levels of miR-22-3p identify patients with systolic heart failure using 30 stable chronic systolic heart failure patients and 30 controls.<sup>24</sup> This seeming discrepancy with our study could possibly be explained by differences in study design. While Goren et al focused on diagnostic properties of miR-22-3p by comparing cases and controls, we focused on prognostic value of miR-22-3p in patients with established CHF. To the best of our knowledge, other cardiovascular studies on miR-22-3p in human subjects are lacking. Altogether, our study is in line with previous fundamental experiments which demonstrated that loss of miR-22-3p leads to dilatation of myocardium and progressive HF. Our study confirms that lower levels of miR-22-3p are associated with worsening of CHF, and that miR-22-3p may complement established HF biomarkers in prognostication.

Previously, several studies using animal models have shown decreased levels of miR-378a-3p during cardiac remodelling<sup>36</sup> and in HF due to cardiac hypertrophy.<sup>37-39</sup> Furthermore, a significant down-regulation of miR-378a-3p in hearts with dilated cardiomyopathy compared to non-failing control hearts has been observed.<sup>23</sup> Since the presence of miR-378a-3p is required to resist ventricular remodeling during cardiac stress, it may offer therapeutic potential for the management of HF.<sup>38</sup> It has been suggested, that up-regulation of miR-378a-3p could serve as a potential novel treatment for apoptosis and ischemic heart disease, since up-regulation of this miR enhanced cell viability, and inhibited apoptosis and necrosis in myocardium of rats.<sup>40</sup> In the current study, we also observed a tendency towards an inverse association between the temporal pattern of miR-378a-3p and the primary endpoint in univariable models. These results concur with the aforementioned studies.

Another miR that has previously been associated with HF, is miR-423-5p.<sup>19,21,22,24</sup> However, in our study, there was no association between the temporal pattern of miR-423-5p and the primary endpoint. Existing studies on miR-423-5p in humans all compared single measurements in (C)HF patients with measurements in healthy controls, and imply that this miR has diagnostic value for HF.<sup>19,21,24</sup> We

did not evaluate the diagnostic value of miRs, but the prognostic value of serial miR measurements in patients with known CHF. Although miR-423-5p may discriminate between HF patients and healthy controls, it may lack prognostic value in patients with longstanding CHF. Earlier findings support this hypothesis.<sup>20</sup> Bauters et al serially measured serum levels of circulating miR-423-5p in 246 patients with a first anterior Q-wave myocardial infarction, at discharge and subsequently at 3 months and 1 year. They found no association between miR-423-5p levels and indices of left ventricular function and left ventricular remodeling, which were serially assessed during a 1-year period after the index myocardial infarction, nor with B-type natriuretic peptide. They concluded that miR-423-5p is not a useful biomarker of left ventricular remodeling after myocardial infarction.<sup>20</sup>

The selection of the miRs for the current investigation was based on previous studies, which used animal models and relatively small patient groups. Some of these studies have shown associations between miR-1254, miR-345-5p, miR-486-5p and miR-320a and heart failure.<sup>19,21,24,41,42</sup> Again, these were mostly studies that compared HF patients to healthy controls. In our study, we did not find any associations between these miRs and poor outcome in CHF. Multiple other miRs, such as miR-133a,<sup>43</sup> have previously been associated with HF.<sup>44</sup> Serial measurements of these other miRs, which were not investigated in this study, warrant further investigation. This could lead to further improvements in CHF prognostication, as well as tailored adjustment of treatment.

Some aspects of this study warrant consideration. For the current investigation we only used the first round of inclusions of the ongoing Bio-SHiFT study (n=263). It should be noted that the full Bio-SHiFT cohort is designed to have sufficient statistical power to enable correction for multiple testing in case of application of modern, large-scale biomarker measurement methods. However, the current investigation examines only 7 miRs, which were chosen based on pathophysiological considerations. Thus, the current investigation was hypothesis-driven and not data-driven, rendering correction for multiple testing unnecessary in this particular case. Furthermore, with an average follow-up ~1 year, the number of primary endpoints in the current investigation (n=41) was limited, and consequently so was the number of covariables that could be entered into the models. The lack of a replication population is another limitation of the study. Finally, the majority of the patient population was in NYHA functional class I or II, and thus at relatively low risk. Accordingly, the primary outcome was predominantly composed of heart failure hospitalizations. This may have hampered the prognostic information of the

other miRs tested in this study. Future studies using high-risk patient populations should therefore re-investigate the prognostic information carried by repeated assessment of these miRs.

Remarkably, in the present study, the rate of HFPEF was very low compared to other epidemiological studies. This can most likely be attributed to the fact that in the Netherlands, most HFPEF patients are treated by the general practitioner or in secondary referral centres, while the current study was performed in two centres which were both tertiary referral centres. Potential inclusion bias is not a likely reason for the low HPEF rate, because consecutive patients were screened in both participating centres. Moreover, the number of patients on vitamin K antagonists was quite high in this study, most likely due to the high number of patients with left ventricular aneurysms and thrombi, as well as the high number of patients with atrial fibrillation.

***In conclusion***, in patients with stable CHF, the temporal pattern of circulating miR-22-3p is a strong and independent predictor of prognosis. Thus, the use of individual patterns of change of circulating miR-22-3p for CHF prognostication, as well as for tailored adjustment of treatment, warrants further investigation.

## REFERENCES

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur.J.Heart Fail.* 2016;18:891-975.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;62:e147-e239.
3. Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. *Circulation* 2013;127:500-507.
4. de Couto G, Ouzounian M, and Liu PP. Early detection of myocardial dysfunction and heart failure. *Nat Rev Cardiol* 2010;7:334-344.
5. Savarese G, Trimarco B, Dellgrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. *PLoS One.* 2013;8:e58287.
6. Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. *Arch Intern Med* 2010;170:507-514.
7. Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. *Circulation* 2007;116:249-257.
8. Yan RT, White M, Yan AT, et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. *Am J Cardiol* 2005;96:698-704.
9. Troughton R, Michael FG, and Januzzi JL, Jr. Natriuretic peptide-guided heart failure management. *Eur Heart J* 2014;35:16-24.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004;116:281-297.
11. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. *PLoS One.* 2008;3:e3148.
12. Chen JF, Murchison EP, Tang R, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. *Proc Natl Acad Sci U.S A* 2008;105:2111-2116.
13. Costa Martins PA, Bourajjaj M, Gladka M, et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. *Circulation* 2008;118:1567-1576.
14. Creemers EE, Tijssen AJ, and Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? *Circ Res* 2012;110:483-495.
15. Vogel B, Keller A, Frese KS, et al. Refining diagnostic microRNA signatures by whole-miRNome kinetic analysis in acute myocardial infarction. *Clin Chem* 2013;59:410-418.
16. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. *J Am Coll Cardiol* 2012;60:290-299.

17. Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. *Circ Cardiovasc Genet.* 2010;3:499-506.
18. Olivieri F, Antonicelli R, Lorenzi M, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. *Int J Cardiol* 2013;167:531-536.
19. Goldraich LA, Martinelli NC, Matte U, et al. Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression. *Biomarkers* 2014;19:135-141.
20. Bauters C, Kumarswamy R, Holzmann A, et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. *Int J Cardiol* 2013;168:1837-1840.
21. Tijssen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure. *Circ Res* 2010;106:1035-1039.
22. Dickinson BA, Semus HM, Montgomery RL, et al. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. *Eur J Heart Fail.* 2013;15:650-659.
23. Naga Prasad SV, Duan ZH, Gupta MK, et al. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. *J Biol Chem* 2009;284:27487-27499.
24. Goren Y, Kushnir M, Zafrir B, et al. Serum levels of microRNAs in patients with heart failure. *Eur J Heart Fail.* 2012;14:147-154.
25. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2012;33:1787-1847.
26. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J* 2008;29:2388-2442.
27. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. *Eur Heart J* 2007;28:2539-2550.
28. Rao PK, Toyama Y, Chiang HR, et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. *Circ Res* 2009;105:585-594.
29. Rizopoulos D. JM: An R Package for the Joint Modelling of Longitudinal and Time-to-Event Data. *Journal of Statistical Software* 2010;35:1-33.
30. Rizopoulos D. Joint Models for Longitudinal and Time-to-Event Data: With Applications in R. 2012.
31. Li J, Liang S, Yu H, et al. An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. *Gynecol.Oncol.* 2010;119:543-548.

32. Huang ZP, Wang DZ. miR-22 in cardiac remodeling and disease. *Trends Cardiovasc. Med.* 2014;24:267-272.
33. Huang ZP, Chen J, Seok HY, et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. *Circ.Res.* 2013;112:1234-1243.
34. Gurha P, Abreu-Goodger C, Wang T, et al. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. *Circulation* 2012;125:2751-2761.
35. Gupta SK, Foinquinos A, Thum S, et al. Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction. *J.Am.Coll.Cardiol.* 2016;68:1557-1571.
36. Knezevic I, Patel A, Sundaresan NR, et al. A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. *J Biol Chem* 2012;287:12913-12926.
37. Nagalingam RS, Sundaresan NR, Gupta MP, et al. A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. *J Biol Chem* 2013;288:11216-11232.
38. Nagalingam RS, Sundaresan NR, Noor M, et al. Deficiency of Cardiomyocyte-specific MicroRNA-378 Contributes to the Development of Cardiac Fibrosis Involving a Transforming Growth Factor beta (TGFbeta1)-dependent Paracrine Mechanism. *J Biol Chem* 2014;289:27199-27214.
39. Ganesan J, Ramanujam D, Sassi Y, et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. *Circulation* 2013;127:2097-2106.
40. Fang J, Song XW, Tian J, et al. Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes. *Apoptosis.* 2012;17:410-423.
41. Li X, Zhang X, Wang T, et al. Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model. *J Nanosci.Nanotechnol.* 2013;13:5267-5275.
42. Small EM, O'Rourke JR, Moresi V, et al. Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. *Proc Natl Acad Sci U.S A* 2010;107:4218-4223.
43. Besler C, Urban D, Watzka S, et al. Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy. *Eur.J.Heart Fail.* 2016.
44. Vegter EL, van der MP, De Windt LJ, et al. MicroRNAs in heart failure: from biomarker to target for therapy. *Eur.J.Heart Fail.* 2016;18:457-468.

**Supplemental table – Associations between baseline characteristics and miRNAs measured at baseline**

	miR1254a		miR22-3p		miR345-5p		miR378	
	Beta coefficient (95% CI)	P	Beta coefficient (95% CI)	P	Beta coefficient (95% CI)	P	Beta coefficient (95% CI)	P
<b>Age*</b>	0.02 (-0.03 – 0.08)	0.44	-0.04 (-0.09 – 0.01)	0.16	0.00 (-0.04 – 0.05)	0.88	-0.02 (-0.07 – 0.03)	0.34
<b>Male gender</b>	-0.10 (-0.40 – 0.21)	0.53	0.11 (-0.19 – 0.41)	0.46	0.01 (-0.25 – 0.27)	0.92	0.11 (-0.17 – 0.40)	0.42
<b>BMI</b>	0.00 (-0.03 – 0.03)	0.82	0.02 (-0.01 – 0.05)	0.12	0.01 (-0.02 – 0.03)	0.45	0.01 (-0.02 – 0.04)	0.49
<b>HR*</b>	0.05 (-0.01 – 0.11)	0.10	0.00 (-0.06 – 0.06)	0.93	0.02 (-0.03 – 0.07)	0.45	0.03 (-0.03 – 0.08)	0.37
<b>SBP*</b>	-0.01 (-0.05 – 0.02)	0.44	-0.01 (-0.04 – 0.03)	0.62	-0.01 (-0.04 – 0.01)	0.33	-0.02 (-0.06 – 0.01)	0.14
<b>DBP*</b>	-0.01 (-0.08 – 0.06)	0.79	0.00 (-0.07 – 0.06)	0.91	0.00 (-0.06 – 0.05)	0.96	0.01 (-0.05 – 0.07)	0.71
<b>NYHA III/V</b>	-0.10 (-0.41 – 0.21)	0.54	-0.27 (-0.57 – 0.04)	0.086	-0.14 (-0.40 – 0.13)	0.32	-0.24 (-0.53 – 0.04)	0.093
<b>ICMP</b>	-0.34 (-0.61 – -0.06)	0.017	-0.05 (-0.32 – 0.22)	0.73	-0.21 (-0.44 – 0.03)	0.085	-0.23 (-0.49 – 0.02)	0.070
<b>HCMP</b>	0.31 (-0.09 – 0.72)	0.13	-0.25 (-0.65 – 0.14)	0.21	-0.03 (-0.38 – 0.32)	0.86	0.01 (-0.36 – 0.39)	0.95
<b>Renal failure</b>	0.12 (-0.16 – 0.40)	0.39	-0.13 (-0.40 – 0.14)	0.34	-0.12 (-0.37 – 0.11)	0.30	-0.10 (-0.36 – 0.16)	0.45
<b>DM</b>	0.00 (-0.30 – 0.29)	0.97	-0.01 (-0.31 – 0.28)	0.93	-0.04 (-0.29 – 0.22)	0.76	0.03 (-0.24 – 0.31)	0.82
<b>HT</b>	0.29 (0.02 – 0.57)	0.038	-0.02 (-0.29 – 0.25)	0.90	0.09 (-0.15 – 0.33)	0.47	0.08 (-0.18 – 0.34)	0.54
<b>Ever-smoker</b>	0.13 (-0.14 – 0.44)	0.44	-0.16 (-0.46 – 0.14)	0.29	-0.06 (-0.31 – 0.20)	0.67	-0.04 (-0.32 – 0.25)	0.80

Beta coefficients and corresponding 95 % confidence intervals (CIs) were calculated using linear regression with the 10log transformed microRNAs (MIRs) as dependent variables.

BMI = body mass index; COPD = chronic obstructive pulmonary disease; DBP = diastolic blood pressure; DM = diabetes mellitus; HCMP = hypertensive cardiomyopathy; HR = heart rate; HT = hypertension; ICMP = ischemic cardiomyopathy; NYHA = New York heart association class; SBP = systolic blood pressure;

\* Per 5 points increase



**Supplemental table – Associations between baseline characteristics and miRNAs measured at baseline (continued)**

	miR423-5p		miR486-5p		miR320	
	Beta coefficient (95% CI)	P	Beta coefficient (95% CI)	P	Beta coefficient (95% CI)	P
<b>Age*</b>	-0.03 (-0.08 – 0.02)	0.31	-0.02 (-0.06 – 0.03)	0.52	0.00 (-0.04 – 0.06)	0.87
<b>Male gender</b>	0.12 (-0.17 – 0.40)	0.42	0.13 (-0.14 – 0.39)	0.35	0.13 (-0.18 – 0.43)	0.41
<b>BMI</b>	0.00 (-0.03 – 0.03)	0.92	0.01 (-0.02 – 0.03)	0.44	0.00 (-0.02 – 0.03)	0.76
<b>HR*</b>	0.02 (-0.04 – 0.08)	0.48	0.03 (-0.02 – 0.09)	0.22	0.03 (-0.03 – 0.09)	0.30
<b>SBP*</b>	-0.02 (-0.05 – 0.01)	0.30	-0.02 (-0.05 – 0.01)	0.28	-0.01 (-0.05 – 0.02)	0.42
<b>DBP*</b>	-0.01 (-0.07 – 0.05)	0.64	0.00 (-0.06 – 0.06)	0.96	-0.01 (-0.08 – 0.05)	0.68
<b>NYHA III/V</b>	-0.09 (-0.38 – 0.20)	0.54	-0.09 (-0.36 – 0.18)	0.52	-0.02 (-0.33 – 0.29)	0.91
<b>ICMP</b>	-0.21 (-0.46 – 0.05)	0.11	-0.26 (-0.50 – -0.02)	0.035	-0.32 (-0.60 – -0.05)	0.021
<b>HCMP</b>	-0.10 (-0.47 – 0.28)	0.61	0.17 (-0.18 – 0.53)	0.33	0.17 (-0.23 – 0.57)	0.41
<b>Renal failure</b>	-0.05 (-0.31 – 0.20)	0.69	-0.13 (-0.37 – 0.11)	0.30	0.15 (-0.13 – 0.43)	0.30
<b>DM</b>	-0.03 (-0.30 – 0.25)	0.84	0.03 (-0.23 – 0.29)	0.84	-0.11 (-0.41 – 0.19)	0.49
<b>HT</b>	0.08 (-0.17 – 0.34)	0.53	0.00 (-0.24 – 0.24)	0.98	0.12 (-0.16 – 0.39)	0.42
<b>Ever-smoker</b>	-0.07 (-0.35 – 0.22)	0.65	0.00 (-0.27 – 0.27)	0.99	0.08 (-0.22 – 0.39)	0.60

Beta coefficients and corresponding 95 % confidence intervals (CIs) were calculated using linear regression with the 10log transformed microRNAs (MIRs) as dependent variables.

BMI = body mass index; COPD = chronic obstructive pulmonary disease; DBP = diastolic blood pressure; DM = diabetes mellitus; HCMP = hypertensive cardiomyopathy; HR = heart rate; HT = hypertension; ICMP = ischemic cardiomyopathy; NYHA = New York heart association class; SBP = systolic blood pressure;

\* Per 5 points increase